In the field of B cell lymphoma and MM, the usage of IFN-α-based immunotherapies spans two distinct eras: (1) pre-mAb; and (2) post-mAb eras (Table 2). This evidence concerns the gene IFNA1 and B-cell non-Hodgkin lymphoma.